Clinical trials, particularly those focused on rare diseases and oncology, involve far more than just scientific rigor, they require a deeply empathetic and patient-centered approach.

Families dealing with chronic illnesses often carry an invisible burden of trauma, compounded by the rare nature of the diseases. The trauma isn’t just from the initial diagnosis but is a recurring cycle as they face the progressive nature of the illness.

Trauma significantly impacts how families engage with clinical trials. The emotional and cognitive load can lead to:

  • Missed visits and incomplete questionnaires
  • Challenges adhering to strict trial protocols
  • Decision-making driven by urgency or desperation rather than informed choice

A common trauma response, hypervigilance, can unintentionally affect the quality of clinical trial data. Families may become overly focused on symptom monitoring or make decisions influenced by exhaustion and stress, potentially compromising trial integrity. Trust-building is essential, especially given the history of limited access to information and perceived gatekeeping by healthcare providers.

For many, enrolling in a clinical trial—such as those for Duchenne muscular dystrophy—represents both a challenge and a beacon of hope. The decision to participate is laden with emotional complexity, balancing fear with optimism, and often necessitates significant lifestyle changes.

 

Ergomed’s Commitment to Trauma-Informed Patient Engagement

Ergomed leads the way in integrating trauma-informed care into patient engagement by prioritizing safety, trust, and empowerment. Our approach is grounded in five core principles:

  1. Safety: Ensuring both physical and emotional safety for every participant.
  2. Trustworthiness: Maintaining clear, consistent, and transparent communication.
  3. Choice and Control: Empowering participants with agency throughout their trial experience.
  4. Collaboration: Partnering with families as active contributors to the research process.
  5. Empowerment: Fostering resilience and confidence within the patient community.

Recognizing the broader family impact, Ergomed also emphasizes support for siblings and care partners—often overlooked individuals who face their own emotional and practical challenges during clinical trials.

Conclusion

Addressing trauma in clinical trials is not only a compassionate imperative—it is essential for research success and integrity. By embedding trauma-informed strategies, fostering genuine trust, and centering care around patients and their families, clinical trials can generate more reliable data and improve outcomes for all involved.

At Ergomed, the patient is always at the heart of every decision, ensuring we remain authentically patient-centric.

Through this holistic and empathetic approach, the clinical trials community can enhance patient engagement and retention, ultimately accelerating the development of life-changing treatments.